EnGene Holdings Inc (ENGN)
enGene Holdings Inc. (NASDAQ: ENGN) is a common stock listing tied to a clinical-stage biotechnology company focused on genetic medicines. Through its subsidiary enGene, Inc., the business is developing treatments for bladder cancer, including detalimogene voraplasmid, its lead candidate for non-muscle invasive bladder cancer. The company’s pipeline also includes LEGEND, which is in Phase 2 development. The issuer is based in Montreal, Canada, and was formerly known as enGene Therapeutics Inc., reflecting a name change in April 2026.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ENGN
|
$2.52
|
32.7% Upside
|
Undervalued
|
$3.29
|
72.9% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 16, 2026
|
-1.0x
|
0.5x
|
—
|
125.3 M
|
-97.164 M
|
21.0%
|
33.6%
|
6.2
|
—
|
87.8%
|
